Compare PERI & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PERI | CTKB |
|---|---|---|
| Founded | 1999 | 1990 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.5M | 433.8M |
| IPO Year | 2006 | 2021 |
| Metric | PERI | CTKB |
|---|---|---|
| Price | $9.79 | $4.67 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $14.75 | $5.88 |
| AVG Volume (30 Days) | 277.5K | ★ 1.9M |
| Earning Date | 11-12-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $432,361,000.00 | $196,828,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.59 | $5.62 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $2.37 |
| 52 Week High | $11.79 | $7.30 |
| Indicator | PERI | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 41.56 |
| Support Level | $10.03 | $4.79 |
| Resistance Level | $10.17 | $5.16 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.03 | -0.12 |
| Stochastic Oscillator | 19.88 | 3.41 |
Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.